Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 6, 2005, Pages 1250-1256

  Williamson, V ^a   Pyke, A ^a   Sridhara, S ^a   Kelley, R F ^b   Blajchman, M A ^a,c   Clarke, Bryan J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b GENENTECH INC   (United States)

^c CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Coagulation; EGF; FVII; Rabbit; Tissue factor

Indexed keywords

AMINO ACID; BLOOD CLOTTING FACTOR 7; EPIDERMAL GROWTH FACTOR; MUTANT PROTEIN; THROMBOPLASTIN; HYBRID PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SPECIES COMPARISON; SURFACE PLASMON RESONANCE; ANIMAL; BLOOD CLOTTING; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROTEIN ENGINEERING; PROTEIN MICROARRAY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SUBSTITUTION; ANIMALS; BLOOD COAGULATION; CELL LINE; EPIDERMAL GROWTH FACTOR; FACTOR VII; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOPLASTIN; TRANSFECTION;

EID: 24944573654     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01349.x     Document Type: Article

References (45)

1. Hagen FS, Gray CL, O'Hara PJ, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-6.
2. Broze GJ, Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
3. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-33.
4. Versteeg HH. Tissue factor as an evolutionary conserved cytokine receptor: implications for inflammation and signal transduction. Semin Hematol 2004; 41: 168-72.
5. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signalling. J Thromb Haemost 2003; 1: 1495-503.
6. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP. Tissue factor - a receptor involved in the control of cellular properties including angiogenesis. Thromb Haemost 2001; 86: 334-45.
7. Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signalling and metastasis. Thromb Haemost 2001; 86: 757-71.
8. 100 Escherichia coli. Blood 1998; 91: 1609-15.
9. Kelley RF, Yang J, Eigenbrot C, Moran P, Peek M, Lipari M, Kirchhofer D. Similar molecular interactions of factor VII and factor VIa with the tissue factor region that allosterically regulates enzyme activity. Biochemistry 2004; 43: 1223-9.
10. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, Schoenfeld J, Lowe D, Lai J, Rancatore P, Iverson M, Lim A, Chisholm V, Kelley RF, Riederer M, Kirchhofer D. Generation of a humanized, high-affinity anti-tissue factor antibody for use as a novel therapeutic. Thromb Haemost 2001; 85: 379-89.
11. Yang J, Lee GF, Riederer MA, Kelley RF. Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa. Thromb Haemost 2002; 87: 450-8.
12. Dennis MS, Eigenbrot C, Skeleton NJ, Ultsch MH, Santell L, Dwyer MA, O'Connell MP, Lazarus RA. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000; 404: 465-70.
13. Maun HR, Eigenbrot C, Lazarus RA. Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage. J Biol Chem 2003; 278: 21823-30.
14. Chaing S, Clarke BJ, Sridhara S, Chu K, Friedman P, Van Dusen W, Roberts HR, Blajchman M, Monroe DM, High KA. Severe factor VII deficiency caused by mutations abolishing the cleavage site for activation and altering binding to tissue factor. Blood 1994; 83: 3524-35.
15. Leonard BL, Chen Q, Blajchman MA, Ofosu FA, Sridhara S, Yang D, Clarke BJ. Factor VII deficiency caused by a structural variant N57D of the first epidermal growth factor domain. Blood 1998; 91: 142-8.
16. McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EGD. Factor VII deficiency and the factor VII mutation database. Hum Mut 2001; 17: 3-17.
17. Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci USA 1996; 93: 14379-84.
18. 156 contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem 2001; 276: 6616-20.
19. Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis 1984; 14: 440-4.
20. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
21. Ruiz S, Sridhara S, Blajchman MA, Clarke BJ. Expression and purification of recombinant rabbit factor VII. Thromb Res 2000; 98: 203-11.
22. Williamson V, Pyke A, Sridhara, S, Blajchman MA, Clarke BJ. Interspecies exchange mutagenesis of the first epidermal growth factor-like domain of human factor VII. J Thromb Haemost 2003; 1: abstract PO559.
23. Clarke BJ, Sridhara S. Incomplete gamma carboxylation of human coagulation factor VII: differential effects on tissue factor binding and enzymatic activity. Br J Haematol 1996; 93: 445-50
24. Yan SC, Razzano P, Chao B, Walls J, Berg D, McClure D, Grinnell B. Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Biotechnology 1990; 8: 655-61.
25. Sridhara S, Chaing S, High KA, Blajchman MA, Clarke BJ. Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor. Am J Hematol 1996; 53: 66-71.
26. Kelley RF, Costas KE, O'Connell MP, Lazarus RA. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995; 34: 10383-92.
27. Clarke BJ, Ofosu FA, Sridhara S, Bona RD, Rickles FR, Blajchman MA. The first epidermal growth factor domain of human coagulation factor VII is essential for binding to tissue factor. FEBS Lett 1992; 298: 206-10.
28. Chang JY, Stafford DW, Straight DL. The roles of factor VII's structural domains in tissue factor binding. Biochemistry 1995; 34: 12227-32.
29. Clarke BJ, Sridhara S, Blajchman MA, Hatton MWC. Inhibition of the rabbit extrinsic pathway of coagulation: A comparison of rabbit and human FVII structural analogues. Can J Cardiol 2003; 18: abstract 331.
30. Kelley RF, Refino CJ, O'Connell MP, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89: 3219-27.
31. O'Brien DP, Kemball-Cook G, Hutchinson AM, Martin DMA, Johnson DJD, Byfield PGH, Takamiya O, Tuddenham EGD, McVey JH. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Biochemistry 1994; 33: 14162-9.
32. Selzer T, Albeck S, Schreiber G. Rational design of faster associating and tighter binding protein complexes. Nat Struct Biol 2000; 7: 537-41.
33. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost 2003; 1: 1487-94.
34. Seetharam S, Murphy K, Atkins C, Feuerstein G. Cloning and expresssion of rat coagulation factor VII. Thromb Res 2003; 109: 225-31.
35. Leonard BJN, Clarke B J, Sridhara S, Kelley R, Ofosu FA, Blajchman MA. Activation and active site occupation alter conformation in the region of the first epidermal growth factor-like domain of human factor VII. J Biol Chem 2000; 275: 34894-900.
36. 2+ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity. J Biol Chem 1997; 272: 19919-24.
37. Jin J, Perera L, Stafford D, Pedersen L. Four loops of the catalytic domain of factor Vila mediate the effect of the first EGF-like domain substitution on factor VIIa catalytic activity. J Mol Biol 2001; 307: 1503-17.
38. Dickinson CD, Shobe J, Ruf W. Influence of cofactor binding and active site occupancy on the conformation of the macromolecular substrate exosite of factor VIIa. J Mol Biol 1998; 277: 959-71
39. Persson E. Variants of recombinant factor VIIa with increased intrinsic activity. Semin Hematol 2004; 41: 89-92.
40. Harvey SB, Stone MD, Martinez MB, Nelsestuen G. Mutagenesis of the γ-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site. J Biol Chem 2003; 278: 8363-9.
41. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004; 41: 35-9.
42. Sorensen BB, Persson E, Freskgård PO, Kjalke M, Ezban M, Williams T, Rao LVM. Incorporation of an active site inhibitor in factor Vila alters the affinity for TF. J Biol Chem 1997; 272: 11863-8.
43. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC. Antiapoptotic effect of coagulation factor VIIa. Stood 2003; 102: 1708-15.
44. Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH, Bromberg ME. Formation of tissue factor -factor Xa complex promotes cellular signalling and migration of human breast cancer cells. J Thromb Haemost 2003; 2: 93-101.
45. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 2004; 23: 410-7.